Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mescaline is a naturally occurring psychedelic alkaloid of the phenethylamine class. It is most notably found in the peyote cactus (Lophophora williamsii), as well as other cacti such as San Pedro and Peruvian torch. Chemically known as 3,4,5-trimethoxyphenethylamine, it acts primarily as an agonist at central serotonin (5-hydroxytryptamine) receptors—especially the 5‑HT2A receptor—leading to its characteristic hallucinogenic effects[1][2][10]. Mescaline induces vivid visual hallucinations and significant alterations in sensory perception and thought processes. Its effects are similar to those of LSD and psilocybin but require higher doses due to lower potency[2][3][4]. The compound has been used for thousands of years in Native American religious ceremonies but is classified as a Schedule I controlled substance in the United States with no currently accepted medical use[4][5]. Mescaline’s mechanism also includes mild sympathomimetic activity due to its structural similarity to catecholamines[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mescaline.